Access Vascular

Access Vascular develops novel hydrophilic biomaterial vascular access devices, including a midline catheter (HydroMID) and peripherally inserted central catheter (PICC). Their biomaterial is engineered to significantly reduce complications — data cited show up to 6x fewer complications with HydroMID and 99.99% less bacterial adhesion versus polyurethane in a blood-loop model. The company targets hospitals and infusion providers to improve patient outcomes and lower infection and complication rates across acute and home-care settings. Clinical evidence and material innovation are positioned as their core differentiators in transforming vascular access outcomes.